Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nicola Della Valle is active.

Publication


Featured researches published by Nicola Della Valle.


Clinical Drug Investigation | 2006

Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis.

Enzo Ierardi; Nicola Della Valle; Maurizio Cosimo Nacchiero; Vincenzo De Francesco; G. Stoppino; C. Panella

We report the case of a patient with refractory ulcerative colitis who developed cholestatic acute liver damage after a single infusion of infliximab. Unusual aspects of this case were the early onset (after the first administration) of liver damage and the absence of antinuclear antibodies, alcohol intake, hepatotoxic drugs and all known viral and metabolic causes of hepatic injury. Moreover, no serological or morphological findings of primary sclerosing cholangitis were observed. The patient’s liver damage resolved spontaneously within 6 weeks. Although a direct relationship between administration of infliximab and onset of acute liver damage could not be definitely established, our case suggests that infliximab may induce direct liver damage, the course of which is similar to acute cholestatic hepatitis and resolves following withdrawal of the drug.


Scandinavian Journal of Gastroenterology | 2010

Mucosal assessment of tumor necrosis factor alpha levels on paraffined samples: a comparison between immunohistochemistry and real time polymerase chain reaction

Enzo Ierardi; Floriana Giorgio; Rosa Rosania; M. Zotti; S. Prencipe; Nicola Della Valle; Vincenzo De Francesco; C. Panella

Author(s) : Enzo IerardiArticle title : Mucosal assessment of tumor necrosis factor alpha levels on paraffined samples:a comparison between immunohistochemistry and real time polymerase chainreactionArticle no : 483739Dear Author,Please check these proofs carefully. It is the responsibility of the corresponding author to checkagainst the original manuscript and approve or amend these proofs. A second proof is notnormally provided. Informa Healthcare cannot be held responsible for uncorrected errors, even ifintroduced during the composition process. The journal reserves the right to charge for excessiveauthor alterations, or for changes requested after the proofing stage has concluded.The following queries have arisen during the editing of your manuscript and are marked in themargins of the proofs. Unless advised otherwise, submit all corrections using the CATS onlinecorrection form. Once you have added all your corrections, please ensure you press the “SubmitAll Corrections” button.


Journal of Clinical Pathology | 2011

Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis

Enzo Ierardi; Floriana Giorgio; M. Zotti; Rosa Rosania; Mariabeatrice Principi; S. Marangi; Nicola Della Valle; Vincenzo De Francesco; Alfredo Di Leo; Marcello Ingrosso; C. Panella

Background It is known that syndecan 1 in inflammatory bowel diseases is able to migrate from epithelial basolateral site to the stromal area and apical surface of epithelium with a consequent activation and modulation of basic fibroblast growth factor (bFGF), and this process sustains mucosal healing of ulcers. On the other hand, tumour necrosis factor (TNF) α mucosal levels are directly related to the entity of the damage in these disorders. Aim of the study A ‘post-hoc’ retrospective study was performed to estimate mucosal TNF α in rectal biopsies of subjects with ulcerative colitis (UC) before and after effective infliximab therapy and its relationship with syndecan 1, bFGF and endoscopic mucosal healing. Material and methods Paraffin-embedded rectal samples from 12 patients with UC responders to infliximab were analysed for TNF α, syndecan 1 and bFGF before and 6 months after therapy using a real-time reverse transcriptase polymersase chain reaction. Additionally, syndecan 1 location was evaluated by immunohistochemistry. Samples from 12 subjects with irritable bowel symptoms without endoscopic/histological abnormalities represented the control group. Mucosal healing induced by the treatment was defined by an endoscopic Mayo subscore changing from 2–3 to 0. ANOVA plus Student–Newman–Keuls was used for statistical analysis. Results The authors found that in the active disease, an increase in TNF α (p<0.001) is accompanied by raised levels of both syndecan 1 (p<0.005) and bFGF (p<0.005) compared with the control group. Infliximab-induced TNF α decrease to levels similar to controls is associated with both endoscopic mucosal healing and adhesion molecule/growth factor significant reduction. Additionally, syndecan 1 location, which is predominant in the stromal cells and apical epithelium in the active disorder, is quite exclusively located at the basolateral epithelial area in both healed mucosa and controls. Conclusions Balanced interaction among TNF α inhibition by infliximab, syndecan 1 migration, bFGF repair modulation and final adhesion molecule reversal to its normal location might represent a suitable molecular pathway of endoscopic mucosal healing in UC.


World Journal of Gastrointestinal Oncology | 2010

From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways

Enzo Ierardi; Rosa Rosania; M. Zotti; Floriana Giorgio; S. Prencipe; Nicola Della Valle; Vincenzo De Francesco; C. Panella

Hepatocarcinogenesis is a process attributed to progressive genomic changes that alter the hepatocellular phenotype producing cellular intermediates that evolve into hepatocellular carcinoma (HCC). During the preneoplastic phase, the liver is often the site of chronic hepatitis and/or cirrhosis, and these conditions induce liver regeneration with accelerated hepatocyte cycling in an organ that is otherwise proliferatively at rest. Hepatocyte regeneration is accelerated by upregulation of mitogenic pathways involving molecular and genetic mechanisms. Hepatic growth factors, inhibitors and triggers may also play a role. This process leads to the production of monoclonal populations of aberrant and dysplastic hepatocytes that have telomerase re-expression, microsatellite instability, and occasionally structural aberrations in genes and chromosomes. Development of dysplastic hepatocytes in foci and nodules and the emergence of HCC are associated with the accumulation of irreversible structural alterations in genes and chromosomes even if the genomic basis of the malignant phenotype is largely heterogeneous. Therefore, a malignant hepatocyte phenotype may be produced by changes in genes acting through different regulatory pathways, thus producing several molecular variants of HCC. On these bases, a key point for future research will be to determine whether the deletions are specific, due to particular loci in the minimally deleted regions of affected chromosome arms, or whether they are non-specific with loss of large portions of chromosomes or entire chromosome arms leading to passive deletion of loci. The final aim is the possibility of identifying a step where carcinogenetic processes could be terminated.


Journal of Gastroenterology and Hepatology | 2018

Full-spectrum versus standard colonoscopy for improving polyp detection rate: a systematic review and meta-analysis

Antonio Facciorusso; Valentina Del Prete; Vincenzo Buccino; Nicola Della Valle; Maurizio Cosimo Nacchiero; Nicola Muscatiello

Full‐spectrum endoscopy represents a new endoscopic platform allowing a panoramic 330 degree view of the colon, but evidence of its superiority over standard colonoscopy is still lacking. Our study is the first meta‐analysis comparing the efficacy of full‐spectrum endoscopy with standard colonoscopy.


Clinical Gastroenterology and Hepatology | 2017

Comparative Efficacy of Colonoscope Distal Attachment Devices in Increasing Rates of Adenoma Detection: A Network Meta-analysis

Antonio Facciorusso; Valentina Del Prete; Rosario Vincenzo Buccino; Nicola Della Valle; Maurizio Cosimo Nacchiero; Fabio Monica; Renato Cannizzaro; Nicola Muscatiello

BACKGROUND & AIMS Several add‐on devices have been developed to increase rates of colon adenoma detection (ADR). We assessed their overall and comparative efficacy, and estimated absolute magnitude of benefit through a network meta‐analysis. METHODS We searched the PubMed/Medline and Embase database through March 2017 and identified 25 randomized controlled trials (comprising 16,103 patients) that compared the efficacy of add‐on devices (cap; Endocuff; Arc Medical Design Ltd, Leeds, UK, and Endorings; Us Endoscopy, Mentor, OH) with each other or with standard colonoscopy. The primary outcome was ADR; secondary outcomes included rate of polyp detection, and rate of and time to cecal intubation. We performed pairwise and network meta‐analyses, and appraised quality of evidence using Grading of Recommendations Assessment, Development and Evaluation. We estimated the magnitude of increase in ADR by low‐performing endoscopists (baseline ADR, 10%) and high‐performing endoscopists (baseline ADR, 40%) with use of these devices. RESULTS Overall, distal attachment devices increased ADR compared with standard colonoscopy (relative risk [RR], 1.13; 95% CI, 1.03–1.23; low‐quality evidence), with potential absolute increases in ADR to 11.3% for low‐performing endoscopists and to 45.2% for high‐performing endoscopists. In a comparative evaluation, we found low‐quality evidence that Endocuff increases ADR compared with standard colonoscopy (RR, 1.21; 95% CI, 1.03–1.41), with anticipated increases in ADR to 12% for low‐performing endoscopists and to 48% for high‐performing endoscopists. We found very low quality evidence to support the use of Endorings (RR, 1.70; 95% CI, 0.86–3.36) or caps (RR, 1.07; 95% CI, 0.96–1.19) vs standard colonoscopy for increasing ADR. The benefit of one distal attachment device over another was uncertain due to very low quality evidence. CONCLUSIONS Based on network meta‐analysis, we anticipate only modest improvement in ADRs with use of distal attachment devices, especially in low‐performing endoscopists.


Journal of Crohns & Colitis | 2013

Alimentary disorders in young females with irritable bowel syndrome or ulcerative procto-sigmoiditis: A preliminary report

Nicola Della Valle; Mariabeatrice Principi; Enzo Ierardi

Dear Sir, Distal ulcerative colitis (procto-sigmoiditis; distal UC), functional diseases (irritable bowel syndrome — IBS) as well as eating disorders are frequently found in young females in Western countries. Indeed, in Europe and North America with high-rate of inflammatory bowel diseases in young subjects,1 there is a large availability of food despite female attractiveness is linked to thinness.2 They refer to a group of chronic psychiatric conditions which may involve either scarce or excessive food intake with a damage of physical and mental health.3 The association between organic and/or functional intestinal diseases may be interesting especially in a high risk …


Journal of Anesthesia and Clinical Research | 2014

A Prospective, Randomized Comparative Study of Respiratory and Hemodynamic Monitoring during Colonoscopy using Remifentanyl Versus Propofol/Fentanyl

Giuseppina Mollica; Lucia Mirabella; Savino Spadaro; Nicola Muscatiello; Nicola Della Valle; Gabriele Racanelli; Girolamo Caggianelli; Pasquale Del Vecchio; C. Panella; Enzo Ierardi; Michele Dambrosio; Gilda Cinnella

Objective: We hypothesized that remifentanil continuous infusion during colonoscopy in spontaneous respiration may give benefits in terms of quality of sedation and recovery compared to propofol, and that patients’ ventilatory drive and consciousness could be accurately evaluated by the continuous measurement of end-tidal CO2 (EtCO2), and of Bispectral Score (BIS) respectively. Methods: One-hundred and eighty patients scheduled for colonoscopy were randomized in two groups: 76 patients were included in Groupcontrol (propofol 0.5 mg/kg bolus plus infusion 1 mg/kg/h) and 78 patients in Gruopremi (0.5 mcg/Kg/1 min bolus plus infusion 0.08 mcg/kg/min, progressively reduced to 0.03 mcg/kg/min). Cardiovascular and respiratory variables were measured before induction and every 3 min throughout the procedure. Sedation level was estimated by BIS and Observer’s Assessment of Alertness/Sedation Scale (OAA/S). Respiratory function was evaluated by arterial oxygen saturation (SaO2) and EtCO2. Recovery from sedation and hospital discharge criteria were assessed by Modified Aldrete Score System (APRS) 30 min after colonoscopy completion. Results: Remifentanil was effective and well tolerated during colonoscopy. Hemodynamic parameters remained stable throughout the study steps in both groups. In Groupremi OAA/S and BIS score were higher (p<0.001), and EtCO2 (p<0.5) lower that in Groupcontrol. Recovery time was faster in the Groupremi (p<0.01). Conclusions: Our data show that analgosedation with remifentanil allowed to obtain a good quality colonoscopy without respiratory and hemodynamic impairment and with faster recovery than moderate sedation propofol/fentanyl. Moreover, BIS and EtCO2 monitoring proved to be well suited to evaluate the trend variations of patients’ sedation level and respiratory drive.


Inflammatory Bowel Diseases | 2006

Infliximab single administration followed by acute liver injury

Enzo Ierardi; Nicola Della Valle; Maurizio Cosimo Nacchiero; Vincenzo De Francesco; G. Stoppino; C. Panella


BMC Medical Imaging | 2016

Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers

Luca Pio Stoppino; Nicola Della Valle; Stefania Rizzi; Elsa Cleopazzo; Annarita Centola; Donatello Iamele; Christos Bristogiannis; G. Stoppino; Roberta Vinci; Luca Macarini

Collaboration


Dive into the Nicola Della Valle's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M. Zotti

University of Foggia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge